Clinicians should consider neurosarcoidosis and MOGAD in patients on TNF-α-inhibitors presenting with neurological deficits, even in the absence of radiological findings. Early discontinuation of the triggering agent and timely corticosteroid therapy are essential for favorable outcomes.

The study examined data from the first quarter of 2014 through the first quarter of 2025 to analyze adverse event signals and the time of occurrence between intravenous and subcutaneous infliximab administration...AEs and the time of onset vary across different administration routes of infliximab. Consequently, clinicians should consider these differences when selecting the administration route to balance therapeutic efficacy with the risk of adverse reactions.

The patient developed severe ulcerative colitis and pyoderma gangrenosum refractory to corticosteroids but showed rapid improvement after infliximab therapy, with endoscopic evidence of mucosal improvement. This case highlights a potential role for tumor necrosis factor-α (TNF-α) blockade in reversing severe immune dysregulation induced by IL-6 and IGF-1 inhibition.

Treatment with low-dose Len in transfusion-independent del(5q) MDS reduced the mutational burden of most genes and did not promote the expansion of preexisting clones or AML progression, especially TP53-mutated clones. Early administration of Len in del(5q) MDS patients without TD may be an effective therapeutic approach with a manageable safety profile regarding clonal evolution.

In ivGC-refractory ASUC cases, IFX and tacrolimus showed comparable effectiveness and safety. Similar outcomes were observed despite a more treatment-refractory profile in the tacrolimus group. These findings support the use of either agent as a feasible salvage option in this clinical setting.

Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.

We report the case of a 39-year-old pregnant woman with ileal Crohn's disease who developed severe, life-threatening disseminated tuberculosis during treatment with infliximab and azathioprine. The case highlights the possibility of involvement of atypical sites, such as the placenta. In endemic areas, a high index of suspicion is required for uncommon manifestations of the disease.

Systemic therapy comprised methotrexate and tumor necrosis factor-alpha (TNF-α) inhibitors. In this patient, systemic inflammatory markers did not reliably reflect intraocular disease activity, and infliximab achieved durable remission of Blau-associated uveitis refractory to adalimumab. Although limited to a single observation, the long-term outcome supports infliximab as a salvage option in refractory pediatric Blau-associated uveitis and underscores the value of ophthalmologic-rather than serological-monitoring of disease activity.

P1, N=20, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting

P2, N=30, Completed, Northwestern University | Active, not recruiting --> Completed

Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted.